[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364315-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364315-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","longer-survival-with-precision-medicine-in-late-stage-cancer-patients-original-article","Longer survival with precision medicine in late-stage cancer patients - Original Article","","Per-protocol analysis assessed overall survival in treatment-refractory, end-stage cancer patients discussed at the National Molecular Tumor Board, comparing targeted treatment to no targeted treatment. Patients were prospectively included at a single center and underwent whole exome and RNA sequencing (tumor-normal), with cases reviewed for targeted options via basket trials, compassionate use, or early clinical trials. From 2020–2023, 196 patients were included; driver variants were found in nearly all, and druggable targets were identified in 42%. Although suggested therapy was not widely initiated, treated patients showed improved median overall survival and multivariate predictors of benefit.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/longer-survival-with-precision-medicine-in-late-stage-cancer-patients-original-article/364315/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/longer-survival-with-precision-medicine-in-late-stage-cancer-patients-original-article/364315.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary goal of this study?","Question",{"text":63,"@type":64},"To assess overall survival outcomes of targeted treatment compared with no targeted treatment in molecularly profiled, end-stage cancer patients discussed at the National Molecular Tumor Board.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients and molecular data obtained?",{"text":68,"@type":64},"Patients were prospectively included at a single oncological center and underwent whole exome and RNA sequencing (tumor-normal). Cases were presented at the NMTB to discuss targeted treatment options.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about survival?",{"text":72,"@type":64},"Median overall survival was longer for patients receiving targeted treatment (15 months) than for those not receiving targeted treatment, including those with druggable targets not initiated (5 and 6 months). Multivariate analysis linked targeted treatment with improved overall survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364315,1790240986,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","ORIGINAL ARTICLE  \nLonger survival with precision medicine in late-stage cancer patients5  \nC. K. Mapendano1y, A. K. Nøhr2y, M. Sønderkær3, 4, A. Pagh1, A. Carus1, 4, T. Lörincz1, C. A. Haslund1, L. Ø . Poulsen1, 4,  \nA. Ernst3, 4, J. S. Bødker3, 4, S. C. Dahl2, L. Sunde4 , 5, A. H. Brügmann4, 6, C. Vesteghem2 , 4, I. S. Pedersen3, 4 & M. Ladekarl1, 4􀀂 1Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg; 2Center for Clinical Data Science, Aalborg University and Aalborg University Hospital, Aalborg; 3Molecular Diagnostics and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg; 4Department of Clinical Medicine, Aalborg University, Aalborg; 5Department of Clinical Genetics and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg; 6Department of Pathology, Aalborg University Hospital, Aalborg, Denmark  \nAvailable online xxx  \nBackground: In a per-protocol analysis of molecularly profiled patients with treatment-refractory, end-stage cancer discussed at the National Molecular Tumor Board (NMTB), we aimed to assess the overall survival (OS) outcome of targeted treatment compared with no targeted treatment.  \nMaterials and methods: Patients were prospectively included at a single oncological center. Whole exome and RNA sequencing (tumor-normal) were carried out, and cases were presented at the NMTB for discussion of targeted treatment. Treatment was available through a basket trial, by compassionate use or in early clinical trials.  \nResults: One hundred and ninety-six patients were included from 2020 to 2023 . In all but three patients a driver variant was disclosed, while 42% had simultaneous affection of more than three oncogenic pathways. In 42% of patients adruggable target was identified but two-thirds did not receive the suggested treatment. The fraction of patients initiating treatment yearly rose from 8% to 22% . For patients treated (N ¼ 30), the clinical benefit rate was 44% and median time on treatment was 3.5 months. Druggable targets were enriched in lung cancers, while patients receiving or not receiving targeted treatment had similar clinical characteristics. The median OS was longer for patients receiving targeted treatment (15 months), but similar for patients with no druggable target and suggested targeted treatment not initiated (5 and 6 months, respectively) (P ¼ 0.004) . In multivariate analysis, targeted treatment (hazard ratio 0.43, confidence interval 0.25-0.72), few metastatic sites, and adenocarcinoma histology were predictive of improved OS while alterations of the RTK/RAS pathway were prognostically unfavorable. Conclusions: Tissue-agnostic targeted treatment based on molecular tumor profiling is possible in an increasing fraction of end-stage cancer patients. In those who receive targeted treatment, results strongly suggest a significant survival benefit.  \nKey words: precision medicine, prognosis, tissue agnostic, clinical trial, molecular pathway analysis  \nINTRODUCTION  \nToday, precision medicine in cancer as part of standard of care is mostly based on targeting molecular alterations in tumors of specific tissue types or anatomical sites of origin.2 This is due to randomized studies reporting robust outcomes observed with specific targeted therapies in patients selected by tumor type, compared with nonselective treatments such as chemotherapy.3 However, next-generation sequencing  \n*Correspondence to: Prof. Morten Ladekarl, Department of Oncology, Aalborg University Hospital, Hobrovej 18, 9000 Aalborg, Denmark. Tel: þ45-6139- 9326  \n[E-mail:](E-mail: morten.ladekarl@rn.dk)[ morten.ladekarl@rn.dk](E-mail: morten.ladekarl@rn.dk) (M. Ladekarl).  \nyThese authors share first authorship.  \n5Note: This study was previously presented in part at the ESMO MAP congress 2023.1  \n2059-7029/© 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND licen","cbCainj9Baxu9OOj","https://ap.wps.com/l/cbCainj9Baxu9OOj","pdf",685763,12,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the primary goal of this study?\",\"answer\":\"To assess overall survival outcomes of targeted treatment compared with no targeted treatment in molecularly profiled, end-stage cancer patients discussed at the National Molecular Tumor Board.\"},{\"question\":\"How were patients and molecular data obtained?\",\"answer\":\"Patients were prospectively included at a single oncological center and underwent whole exome and RNA sequencing (tumor-normal). Cases were presented at the NMTB to discuss targeted treatment options.\"},{\"question\":\"What did the results show about survival?\",\"answer\":\"Median overall survival was longer for patients receiving targeted treatment (15 months) than for those not receiving targeted treatment, including those with druggable targets not initiated (5 and 6 months). Multivariate analysis linked targeted treatment with improved overall survival.\"}]","Longer survival with precision medicine in late-stage cancer patients - Original Article | PDF",1790156920]